Name (Synonyms) | Correlation | |
---|---|---|
drug1280 | Ivermectin Pill Wiki | 1.00 |
drug613 | Combined ART/hydroxychloroquine Wiki | 1.00 |
drug527 | Carotid Artery Reactivity Testing Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai population. Outcomes include safety and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.
Description: Comparison of adverse event rates between treatment arms
Measure: Adverse event rates Time: after first dose until day 28 of follow upDescription: comparison of median duration for detectable SAR-CoV2 by PCR from NP swab in each arm
Measure: Efficacy for shortening duration of SAR-CoV2 detection by PCR Time: weekly after treatment until 4th weekDescription: comparison of median duration for total antibody detection in each arm
Measure: Antibody detection rates Time: weekly after treatment until 4th week